Skip to content

RAAS and Arterial Stiffness in SCI

Orthostatic Blood Pressure and Arterial Stiffness in Persons With SCI: The Effect of RAAS System

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04510974
Enrollment
33
Registered
2020-08-12
Start date
2018-06-30
Completion date
2020-12-01
Last updated
2025-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Stiffness, Hypotension, Orthostatic Hypotension, Renin Angiotensin Aldosterone System, Spinal Cord Injury

Brief summary

The study is examining differences in central arterial stiffness, orthostatic changes in blood pressure, norepinephrine, and plasma renin in individuals with spinal cord injury compared with age-matched uninjured controls.

Detailed description

The study is examining differences in central arterial stiffness, orthostatic changes in blood pressure, norepinephrine, and plasma renin in individuals with spinal cord injury compared with age-matched uninjured controls. Arterial stiffness and blood pressure will be collected in the laying down position. A blood sample of norepinephrine and plasma renin will also be collected. The participant will tilt to 30, 45 and 60 degrees for 10 minutes at each angel. Blood pressure and heart rate will be monitored at each angle. Another blood sample of renin and norepinephrine will be collected at the end of 10 minutes at 60 degrees.

Interventions

OTHERSpinal Cord Injury

Spinal Cord Injury

Sponsors

Kessler Foundation
CollaboratorOTHER
Seton Hall University
CollaboratorOTHER
James J. Peters Veterans Affairs Medical Center
Lead SponsorFED

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
21 Years to 70 Years

Inclusion criteria

* SCI participants: * injured between C1-T1 and T6-T12 * wheelchair dependent * AIS classification A, B or C * Injured occurred more than 1 year ago

Exclusion criteria

* currently have an illness or infection * current smoker of at least 1 year * controlled or uncontrolled hypertension or diabetes mellitus * Neurological condition other than SCI (Alzheimer's disease, dementia, stroke, multiple sclerosis, Parkinson's disease) * cardiovascular disease (coronary heart disease, congestive heart failure, peripheral artery disease)

Design outcomes

Primary

MeasureTime frameDescription
Pulse Wave Velocity (m/s)2 yearsDetermine average pulse wave velocity among the three groups.

Secondary

MeasureTime frameDescription
Systolic Blood Pressure (mmHg)2 yearsDetermine differences in blood pressure among groups
Plasma Renin (pg/ml)2 yearsDetermine differences in plasma renin among the groups
Norepinephrine (pg/ml)2 yearsDetermine differences in plasma norepinephrine among the groups.

Countries

United States

Participant flow

Participants by arm

ArmCount
Cervical SCI
Ages between 21-70 years old Injured between C1-T1 Wheelchair dependent AIS classification of A, B or C Injury occurred more than 1 year ago Spinal Cord Injury: Spinal Cord Injury
11
Thoracic SCI
Ages between 21-70 Injured between T6-T12 Wheelchair dependent AIS classification of A, B or C Injury occurred more than 1 year ago Spinal Cord Injury: Spinal Cord Injury
11
Able-bodied Control
Ages between 21-70
11
Total33

Baseline characteristics

CharacteristicCervical SCIThoracic SCIAble-bodied ControlTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
11 Participants11 Participants11 Participants33 Participants
Age, Continuous45 years
STANDARD_DEVIATION 13
43 years
STANDARD_DEVIATION 11
45 years
STANDARD_DEVIATION 13
44 years
STANDARD_DEVIATION 12
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants0 Participants1 Participants3 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants11 Participants10 Participants30 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Region of Enrollment
United States
11 participants11 participants11 participants33 participants
Sex: Female, Male
Female
3 Participants2 Participants2 Participants7 Participants
Sex: Female, Male
Male
8 Participants9 Participants9 Participants26 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 110 / 110 / 11
other
Total, other adverse events
0 / 110 / 110 / 11
serious
Total, serious adverse events
0 / 110 / 110 / 11

Outcome results

Primary

Pulse Wave Velocity (m/s)

Determine average pulse wave velocity among the three groups.

Time frame: 2 years

ArmMeasureValue (MEAN)Dispersion
Cervical SCIPulse Wave Velocity (m/s)8.81 m/sStandard Deviation 1.91
Thoracic SCIPulse Wave Velocity (m/s)7.36 m/sStandard Deviation 1.58
Able-bodied ControlPulse Wave Velocity (m/s)5.53 m/sStandard Deviation 0.95
Secondary

Norepinephrine (pg/ml)

Determine differences in plasma norepinephrine among the groups.

Time frame: 2 years

ArmMeasureValue (MEAN)Dispersion
Cervical SCINorepinephrine (pg/ml)176.0 pg/mLStandard Deviation 90
Thoracic SCINorepinephrine (pg/ml)515.6 pg/mLStandard Deviation 162.3
Able-bodied ControlNorepinephrine (pg/ml)371.8 pg/mLStandard Deviation 118.3
Secondary

Plasma Renin (pg/ml)

Determine differences in plasma renin among the groups

Time frame: 2 years

ArmMeasureValue (MEAN)Dispersion
Cervical SCIPlasma Renin (pg/ml)24.9 pg/mLStandard Deviation 13.9
Thoracic SCIPlasma Renin (pg/ml)21.9 pg/mLStandard Deviation 18
Able-bodied ControlPlasma Renin (pg/ml)16.0 pg/mLStandard Deviation 7.4
Secondary

Systolic Blood Pressure (mmHg)

Determine differences in blood pressure among groups

Time frame: 2 years

ArmMeasureValue (MEAN)Dispersion
Cervical SCISystolic Blood Pressure (mmHg)95 mmHgStandard Deviation 20
Thoracic SCISystolic Blood Pressure (mmHg)125 mmHgStandard Deviation 14
Able-bodied ControlSystolic Blood Pressure (mmHg)128 mmHgStandard Deviation 27

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026